At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06386705Phase 1RecruitingUpdate OverdueUpdated 23mo ago · Completion was 6mo agoA Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.
In Brief
A Phase 1 clinical trial evaluating TSN084 for Malignant Neoplasm. Currently recruiting, targeting 114 participants across 2 sites.
Signals
Detailed Summary
TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China.
Study Details
Timeline
Interventions
TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.